Thomas R Moench
Overview
Explore the profile of Thomas R Moench including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1411
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hoang T, Toler E, DeLong K, Mafunda N, Bloom S, Zierden H, et al.
PLoS Pathog
. 2020 Jan;
16(1):e1008236.
PMID: 31971984
Bacterial vaginosis (BV), a condition in which the vaginal microbiota consists of community of obligate and facultative anaerobes rather than dominated by a single species of Lactobacillus, affects ~30% of...
12.
OHanlon D, Come R, Moench T
BMC Microbiol
. 2019 Jan;
19(1):13.
PMID: 30642259
Background: Lactic acid (protonated lactate) has broad antimicrobial activity. Vaginal lactobacilli produce lactic acid, and are known to confer protection against reproductive tract infections when they are predominant in the...
13.
Tyssen D, Wang Y, Hayward J, Agius P, DeLong K, Aldunate M, et al.
mSphere
. 2018 Jul;
3(4).
PMID: 29976641
Women of reproductive age with a dominated vaginal microbiota have a reduced risk of acquiring and transmitting HIV and a vaginal pH of ~4 due to the presence of ~1%...
14.
Zhao C, Gunawardana M, Villinger F, Baum M, Remedios-Chan M, Moench T, et al.
Antimicrob Agents Chemother
. 2017 Apr;
61(7).
PMID: 28416548
The broadly neutralizing antibody (bNAb) VRC01, capable of neutralizing 91% of known human immunodeficiency virus type 1 (HIV-1) isolates , is a promising candidate microbicide for preventing sexual HIV infection...
15.
Stalter R, Moench T, MacQueen K, Tolley E, Owen D
J Int AIDS Soc
. 2016 May;
19(1):20746.
PMID: 27142091
Introduction: Poor adherence to product use has been observed in recent trials of antiretroviral (ARV)-based oral and vaginal gel HIV prevention products, resulting in an inability to determine product efficacy....
16.
Moench T
J Infect Dis
. 2014 Nov;
210 Suppl 3:S654-9.
PMID: 25414420
Small-animal models of lentivirus transmission have repeatedly demonstrated transmission by cell-associated virus via vaginal, rectal, and oral routes. The earliest experiments were in the cat/feline immunodeficiency virus model, followed a...
17.
OHanlon D, Moench T, Cone R
PLoS One
. 2013 Nov;
8(11):e80074.
PMID: 24223212
Lactic acid at sufficiently acidic pH is a potent microbicide, and lactic acid produced by vaginal lactobacilli may help protect against reproductive tract infections. However, previous observations likely underestimated healthy...
18.
Moench T, OHanlon D, Cone R
Sex Transm Dis
. 2012 Apr;
39(5):335-40.
PMID: 22504592
Background: An objective and accurate method that measures adherence to vaginal microbicide gel regimens during clinical trials could provide more accurate estimates of microbicide efficacy, aid in targeting adherence promotion...
19.
Vincent K, Stanberry L, Moench T, Breitkopf C, Loza M, Wei J, et al.
Obstet Gynecol
. 2011 Nov;
118(6):1354-1361.
PMID: 22105265
Objective: Colposcopy has been used to detect epithelial damage with vaginal microbicides. In animal models, optical coherence tomography provided increased sensitivity over colposcopy in detecting epithelial injury. This randomized, double-blinded,...
20.
Price C, Tyssen D, Sonza S, Davie A, Evans S, Lewis G, et al.
PLoS One
. 2011 Sep;
6(9):e24095.
PMID: 21935377
Unlabelled: SPL7013 Gel (VivaGel(®)) is a microbicide in development for prevention of HIV and HSV. This clinical study assessed retention and duration of antiviral activity following vaginal administration of 3%...